37
Participants
Start Date
February 28, 2013
Primary Completion Date
November 11, 2016
Study Completion Date
July 12, 2018
Maraviroc 300 mg
Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Abramson Cancer Center at Penn Medicine
OTHER